Clinical trials: Crow's Feet Lines
Lateral Canthal Lines, Crow's Feet
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called crow's feet, also known as…
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT01064518
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01189760
- Testing
- onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 917 people
- Sponsor
- Allergan
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL)…
- Trial name
- NCT04259086
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 8 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, LCL, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT04985916
- Testing
- Vehicle, botulinum toxin, Type A
- Where
- 19 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eirion Therapeutics Inc.
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01224015
- Testing
- normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- Allergan
Lateral Canthal Lines, Crows Feet
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
The purpose of this study is to confirm the effect of ANT-1401 in the treatment of Lateral Canthal Lines.
- Trial name
- NCT01809964
- Testing
- ANT-1401, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Crow's Feet Lines
Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines
To determine the efficacy and safety of Botulax® in treatment of crow's feet line
- Trial name
- NCT03408236
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hugel
Crow's Feet Lines
A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement
The objective of this Pilot Study is to verify the safety and efficacy of DMSB01 in the temporary improvement of Crow's Feet Lines
- Trial name
- NCT06402058
- Testing
- DMSB01, Rejuran®
- Volunteers
- 60 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Skin Aging
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines
- Trial name
- NCT01940991
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, LCL, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03912805
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eirion Therapeutics Inc.
Lateral Canthus Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Crow's Feet Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).
- Trial name
- NCT01797081
- Testing
- botulinum toxin Type A (24 U), botulinum toxin Type A (12 U), Normal Saline
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Allergan
Upper Facial Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Upper Facial Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
- Conditions
- Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
- Trial name
- NCT01797094
- Testing
- botulinum toxin Type A (44U), botulinum toxin Type A (32U)
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Allergan
Lateral Canthal Lines, Crow's Feet
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the efficacy and safety of a single administration of RT001 compared to placebo gel for the treatment of moderate to severe lateral canthal lines.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968825
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, Crow's Feet Lines
BOTOX® in the Treatment of Crow's Feet Lines in China
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).
- Trial name
- NCT02195687
- Testing
- botulinum toxin Type A, Normal Saline
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Allergan
Crow's Feet Lines
To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet
This clinical study is a confirmatory clinical study to prove that the test device, DLMR01, is non-inferior to the control device, Rejuran®, in terms of temporary wrinkle improvement effect on crow's feet and safety.
- Trial name
- dermal filler (NCT06376838)
- Testing
- DLMR01, Rejuran
- Where
- South Korea
- Volunteers
- 218 people
- Sponsor
- DEXLEVO
Wrinkle
Study to Identify if Saie Beauty's Under Eye Concealer Works to Improve Under-Eye Skin Appearance and Reduce Imperfections
Saie Beauty has developed 'Hydrabeam Sheer Brightening Under Eye Concealer' that is specifically designed for improving under-eye skin health.
- Trial name
- NCT05231681
- Testing
- Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Saie Beauty
Lateral Canthal Lines
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, the number of randomised, controlled…
- Trial name
- NCT00247559
- Testing
- Botulinum toxin type A
- Where
- 9 sites in France, Germany and 1 more
- Volunteers
- 221 people
- Sponsor
- Ipsen
Canthal Lines
A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
This double-blind study has two parts for each subject (same population): Part A: initial treatment in Lateral Canthal Lines (LCL) (placebo-controlled): To assess the efficacy and safety of Azzalure® compared to placebo in the…
- Trial name
- NCT01308060
- Testing
- Botulinum Toxin Type A
- Volunteers
- 335 people
- Sponsor
- Galderma R&D
Lateral Canthal Lines, Crow's Feet
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.
- Trial name
- NCT01358695
- Testing
- ANT-1207, Botulinum Toxin, Type A, Botulinum Toxin Type A
- Where
- 6 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03655691
- Testing
- Vehicle, botulinum toxin, Type A
- Where
- 6 sites in United States
- Volunteers
- 79 people
- Sponsor
- Eirion Therapeutics Inc.